
Pharma Pulse 5/7/25: Teva Pharmaceutical’s Branded Drugs Boost First Quarter Profit, Theriva Biologics Announces Positive VIRAGE Phase IIb Results
Teva Pharmaceutical’s first-quarter profit beat expectations thanks to surging sales of key branded drugs for migraines, Huntington’s disease, and schizophrenia, as the company continues shifting toward innovative therapies while maintaining its generics focus.
Theriva Biologics reported positive Phase IIb results showing that VCN-01, combined with standard chemotherapy, significantly improved survival outcomes in metastatic pancreatic cancer, supporting its potential as a promising new treatment.
In a Q&A with Pharmaceutical Executive, Jesse Mendelsohn, VP at Model N, cautions that proposed US drug tariffs may raise manufacturing costs without meaningfully reshoring production, and instead advocates for alternative strategies like domestic manufacturing incentives, structured Medicare negotiations, and enhanced pricing analytics to reduce drug costs and protect supply chains.
In this Applied Clinical Trials article, industry experts outline four strategic considerations for selecting an electronic data capture system amid the evolving clinical data landscape (EDC), emphasizing that modern EDCs must support automation, integrate seamlessly with clinical data workbenches, and enable real-time access to reconciled, cross-source data in order to meet the demands of adaptive trials and multi-vendor environments.
Artificial intelligence is transforming pharmacy practice by streamlining workflows, enhancing clinical decision-making, and enabling pharmacists to shift into more consultative roles, provided they actively engage in shaping these tools to preserve the human element of patient care.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.